- Regenxbio (RGNX, Financial) shares soar following FDA endorsement.
- Analysts foresee significant upside potential based on target prices.
- GuruFocus estimates suggest Regenxbio is undervalued with an impressive growth outlook.
Gene therapy stocks, including Regenxbio (RGNX), have seen a notable uptick in their market performance. This surge is largely attributed to optimistic remarks made by FDA Commissioner Martin Makary. In a recent SiriusXM interview, Makary discussed a promising new development pathway for gene therapies aimed at rare diseases, significantly bolstering investor confidence in this innovative sector.
Wall Street Analysts' Insights
According to the one-year price targets from 12 financial analysts, Regenxbio Inc (RGNX, Financial) is projected to reach an average target price of $32.92. The forecasts range from a high of $52.00 to a low of $12.00, implying a substantial upside of 395.36% from its current trading price of $6.65. More details on these projections can be accessed on the Regenxbio Inc (RGNX) Forecast page.
The average brokerage recommendation for Regenxbio Inc (RGNX, Financial), provided by 12 brokerage firms, stands at 1.8. This rating indicates an "Outperform" status on a scale where 1 represents a Strong Buy and 5 a Sell.
Evaluating GF Value
GuruFocus provides an estimated GF Value for Regenxbio Inc (RGNX, Financial) at $36.00 for the coming year. This estimation suggests an impressive upside of 441.76% from the current market price of $6.645. The GF Value represents GuruFocus' fair value estimate, derived from historical trading multiples, past business growth, and future business performance forecasts. For a more detailed assessment, visit the Regenxbio Inc (RGNX) Summary page.
